Drugs for Mixed Cell Type Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 95)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Gemcitabine |
Approved |
Phase 2, Phase 3 |
|
95058-81-4, 122111-03-9 |
60750 |
Synonyms:
2',2'-DFDC
2',2'-Difluoro-2'-deoxycytidine
2',2'-Difluorodeoxycytidine
2'-Deoxy-2',2'-difluorocytidine
2'-Deoxy-2',2''-difluorocytidine-5'-O-monophosphate
2'-Deoxy-2'-difluorocytidine
4-Amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
DDFC
DFDC
DFdCyd
Gemcin
GEMCITABIN
Gemcitabina
Gemcitabina [INN-Spanish]
GEMCITABINE
GEMCITABINE HCL
|
Gemcitabine hydrochloride
gemcitabine hydrochloride|Gemzar®
Gemcitabine, (alpha-D-threo-pentofuranosyl)-isomer
Gemcitabine, (beta-D-threo-pentafuranosyl)-isomer
Gemcitabine, (D-threo-pentafuranosyl)-isomer
Gemcitabinum
Gemcitabinum [INN-Latin]
Gemtro
Gemzar
GEO
INFUGEM
LY188011
LY-188011
LY188011 HYDROCHLORIDE
LY-188011 HYDROCHLORIDE
NSC-613327
|
|
2 |
|
Doxorubicin |
Approved, Investigational |
Phase 2, Phase 3 |
|
23214-92-8 |
31703 |
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
ADM
ADR
Adriablastin
Adriablastine
Adriamycin
Adriamycin PFS
Adriamycin RDF
Adriamycin Semiquinone
Adriamycin®|Caelyx® (liposomal doxorubicin)|Doxil®|doxorubicin hydrochloride
Adriblastin
Adriblastina
Adriblastine
Adrimedac
Baxter brand OF doxorubicin hydrochloride
Bedford brand OF doxorubicin hydrochloride
Bristol-myers squibb brand OF doxorubicin hydrochloride
Caelyx
Cell pharm brand OF doxorubicin hydrochloride
Columbia brand OF doxorubicin hydrochloride
DM2
DOXIL
Doxo
Doxo cell
Doxo-cell
Doxolem
DOXORUBICIN
Doxorubicin HCl
Doxorubicin hexal
Doxorubicin hydrochloride
|
Doxorubicin NC
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicina ferrer farm
Doxorubicina funk
Doxorubicina tedec
Doxorubicine
Doxorubicine [INN-French]
Doxorubicine baxter
Doxorubicinum
Doxorubicinum [INN-Latin]
Doxotec
Elan brand OF doxorubicin hydrochloride
Farmiblastina
Ferrer brand OF doxorubicin hydrochloride
Hexal brand OF doxorubicin hydrochloride
Hydrochloride, doxorubicin
HYDROXYDAUNORUBICIN
Kenfarma brand OF doxorubicin hydrochloride
Lemery brand OF doxorubicin hydrochloride
Medac brand OF doxorubicin hydrochloride
Myocet
Neocorp brand OF doxorubicin hydrochloride
NSC-123127
Onkodox
Onkoworks brand OF doxorubicin hydrochloride
Pfizer brand OF doxorubicin hydrochloride
Prasfarma brand OF doxorubicin hydrochloride
RDF Rubex
Resmycin
Ribodoxo
Ribosepharm brand OF doxorubicin hydrochloride
Rubex
Tedec meiji brand OF doxorubicin hydrochloride
Urokit doxo cell
Urokit doxo-cell
VALRUBICIN IMPURITY, DOXORUBICIN
|
|
3 |
|
Topotecan |
Approved, Investigational |
Phase 2, Phase 3 |
|
123948-87-8, 119413-54-6 |
60699 60700 |
Synonyms:
9 Dimethylaminomethyl 10 hydroxycamptothecin
9-[(Dimethylamino)methyl]-10-hydroxy-(4S)-camptothecin
9-Dimethylaminomethyl-10-hydroxycamptothecin
Hycamptamine
HYCAMPTIN
Hycamtamine
Hycamtin
Hydrochloride, nogitecan
Hydrochloride, topotecan
Nogitecan hydrochloride
NSC-609699
Potactasol
SK And F 104864 a
SK And F104864a
SK And F-104864-a
|
SK&F-S-104864A
SKF-104864
SK-S-104864-A
SmithKline beecham brand OF topotecan hydrochloride
Topotecan
TOPOTECAN HCL
Topotecan hydrochloride
Topotecan lactone
Topotecan monohydrochloride, (S)-isomer
Topotecane
Topotecane [INN-French]
Topotecanum
Topotecanum [INN-Latin]
TPT
TTC
|
|
4 |
|
Niraparib |
Approved, Investigational |
Phase 2, Phase 3 |
|
1038915-60-4 |
24958200 |
Synonyms:
COMPOUND 56 [PMID 19873981]
compound 56 [PMID 19873981]|MK 4827|MK-4827|Zejula®
JNJ-64091742
MK 4827
|
MK4827
MK-4827
NIRAPARIB
ZL-2306
|
|
5 |
|
Pertuzumab |
Approved |
Phase 2, Phase 3 |
|
380610-27-5 |
|
Synonyms:
2C4 ANTIBODY
2C4|Omnitarg® (obsolete trade name)|Perjeta®
Immunoglobulin G1, anti-(human v (receptor)) (human-mouse monoclonal 2C4 heavy chain), disulfide with human-mouse monoclonal 2C4 kappa-chain, dimer
LS-185920
MOAB 2C4
MONOCLONAL ANTIBODY 2C4
|
OMNITARG
OMNITARG PERJETA
PERJETA
PERTUZUMAB
RG-1273
RHUMAB-2C4
|
|
6 |
|
Trastuzumab |
Approved, Investigational |
Phase 2, Phase 3 |
|
180288-69-1 |
|
Synonyms:
4D5V8
ABP 980
ABP-980
ANTI HER2
D5v8|Herceptin®|R-597
DMB-3111 (TRASTUZUMAB BIOSIMILAR)
EG12014
EG-12014
HERCEPTIN
IG GAMMA-1 CHAIN C REGION
KADCYLA
|
R-597
RHUMAB HER2
SYD977
SYD-977
TRASTUZUMAB
TRASTUZUMAB BETA
trastuzumab-anns
trastuzumab-dkst
trastuzumab-dttb
trastuzumab-pkrb
trastuzumab-qyyp
|
|
7 |
|
Ifosfamide |
Approved |
Phase 3 |
|
3778-73-2 |
3690 |
Synonyms:
3-(2-Chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
Asta Z 4942
Holoxan
Ifex
Ifosfamid
Ifosfamida
IFOSFAMIDE
Ifosfamide sterile
Ifosfamidum
Ifosphamide
Ifsofamide
Iphosphamid
|
Iphosphamide
I-phosphamide
Iso endoxan
Iso-endoxan
Isofosfamide
Isophosphamide
Isosfamide
MITOXANA
MJF-9325
NSC-109724
Z-4942
|
|
8 |
|
Cyclophosphamide |
Approved, Investigational |
Phase 3 |
|
50-18-0, 6055-19-2 |
2907 |
Synonyms:
(+-)-Cyclophosphamide
(+,-)-2-(Bis(2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
(RS)-Cyclophosphamide
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
Anhydrous cyclophosphamide
Anhydrous, cyclophosphamide
ASTA
Asta B 518
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
Ciclofosfamida
Ciclofosfamide
Clafen
Claphene
CP
CPA
CTX
CY
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide anhydrous
Cyclophosphamide monohydrate
Cyclophosphamide Sterile
Cyclophosphamide, (R)-isomer
Cyclophosphamide, (S)-isomer
Cyclophosphamidum
Cyclophosphan
Cyclophosphane
Cyclophosphoramide
|
Cyclostin
Cyklofosfamid
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan Lyoph
Endoxan
Endoxan R
Endoxana
Endoxanal
Endoxan-Asta
Endoxane
Enduxan
Genoxal
Hexadrin
LEDOXINA
Lyophilized Cytoxan
Mitoxan
Monohydrate, cyclophosphamide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
Neosar
Procytox
Rcra Waste Number U058
Revimmune
Semdoxan
Sendoxan
Senduxan
Zyklophosphamid
|
|
9 |
|
Mechlorethamine |
Approved, Investigational |
Phase 3 |
|
51-75-2 |
4033 |
Synonyms:
2,2'-Dichloro-N-methyldiethylamine
b,Beta'-dichlorodiethyl-N-methylamine
beta,Beta'-dichlorodiethyl-N-methylamine
BIS (2-CHLOROETHYL) METHYLAMINE
Bis(2-chloroethyl)methylamine
Bis(b-chloroethyl)methylamine
Bis(beta-chloroethyl)methylamine
Bis(β-chloroethyl)methylamine
Caryolysine
Chlorethazine
Chlormethine
Chlormethinum
Cloramin
Clormetina
Embichin
HN2
HN-2
Hydrochloride N-oxide, mechlorethamine
Hydrochloride, mechlorethamine
MBA
Mechlorethamine
Mechlorethamine hydrochloride
Mechlorethamine hydrochloride N oxide
Mechlorethamine hydrochloride N-oxide
Mechlorethamine N oxide
Mechlorethamine N-oxide
Mechlorethamine oxide
Mechloroethamine
Mecloretamina
|
Merck brand OF mechlorethamine hydrochloride
Merck frosst brand OF mechlorethamine hydrochloride
Methylbis(2-chloroethyl)amine
Methylbis(b-chloroethyl)amine
Methylbis(beta-chloroethyl)amine
Methylbis(β-chloroethyl)amine
Methylchlorethamine
Mitomen
Mustargen
Mustine
Nitrogen mustard
Nitrogen mustard N oxide
Nitrogen mustard N-oxide
NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE
Nitrogranulogen
Nitromin
N-Methyl-bis(2-chloroethyl)amine
N-Methyl-bis(b-chloroethyl)amine
N-Methyl-bis(beta-chloroethyl)amine
N-Methyl-bis(β-chloroethyl)amine
N-Oxide, mechlorethamine hydrochloride
N-Oxide, nitrogen mustard
NSC 762
NSC-10107
NSC-128663
NSC-762
Β,beta'-dichlorodiethyl-N-methylamine
β,β'-dichlorodiethyl-N-methylamine
|
|
10 |
|
Palifosfamide |
Investigational |
Phase 3 |
|
31645-39-3 |
100427 |
Synonyms:
Ifosfamide mustard
Ifosforamide mustard
IPAM
Iphosphoramide mustard
IPM
Isophosphamide mustard
Isophosphoramide mustard
N,N'-BIS-(2-CHLOROETHYL)PHOSPHORIC ACID
|
N,N'-di-(2-chloroethyl)phosphorodiamidic acid
NN'-Bis-(2-chloroethyl)phosphate
NN'-Bis-(2-chloroethyl)phosphoric acid
NSC-297900
Palifosfamide
Palifosfamide-tris
ZIO-201
Zio-201isophosphamide mustard
|
|
11 |
|
Antineoplastic Agents, Immunological |
|
Phase 2, Phase 3 |
|
|
|
12 |
|
Liposomal doxorubicin |
|
Phase 2, Phase 3 |
|
|
|
13 |
|
Alkylating Agents |
|
Phase 3 |
|
|
|
14 |
|
Antineoplastic Agents, Alkylating |
|
Phase 3 |
|
|
|
15 |
|
Trabectedin |
Approved, Investigational |
Phase 2 |
|
114899-77-3 |
108150 |
Synonyms:
Ect 743
Ecteinascidin
Ecteinascidin 743
ecteinascidin 743|ET-743|Yondelis®
ECTEINASCIDINS TRABECTEDIN
ET743
|
ET-743
NSC 684766
NSC-648766
Trabectedin
Trabectedina
Yondelis
|
|
16 |
|
Sunitinib |
Approved, Investigational |
Phase 2 |
|
557795-19-4 |
5329102 |
Synonyms:
5-(5-Fluoro-2-oxo-1,2-dihydroindolylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide
SU011248
SU-011248
SU11248
SU-11248
|
SU11248|Sutent®
SUNITINIB
Sunitinib malate
Sunitinibum
Sutent
|
|
17 |
|
Oxaliplatin |
Approved, Investigational |
Phase 2 |
|
61825-94-3 |
43805 11947679 6857599 |
Synonyms:
ACT 078
ACT-078
DACPLAT
Diaminocyclohexane Oxalatoplatinum
Eloxatin
Eloxatine
Elplat
Foloxatine
JM-83
L-OHP
L-OHP CPD
MBP-426 (LIPOSOMAL OXALIPLATIN)
NSC-266046
Oxalatoplatin
|
Oxalatoplatinum
Oxaliplatin
Oxaliplatin [Usan:Inn:Ban]
oxaliplatine
oxaliplatino
Oxaliplatino [Spanish]
oxaliplatinum
Oxaliplatinum [Latin]
Oxaloplatine [French]
Oxaloplatino [Spanish]
RP-54780
SR-96669
Transplatin
|
|
18 |
|
Erlotinib |
Approved, Investigational |
Phase 2 |
|
183319-69-9, 183321-74-6 |
176870 |
Synonyms:
[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
[6,7-Bis(2-methoxy-ethoxy)quinazoline-4-yl]-(3-ethynylphenyl)amine
11C Erlotinib
11C-Erlotinib
CP-358
CP-358,774
CP-358774
CP-35877401
CP-358774-01
ERLOTINIB
Erlotinib HCL
Erlotinib hydrochloride
Erlotinibum
|
HCL, Erlotinib
Hydrochloride, erlotinib
N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine
NSC 718781
NSC 718781|OSI 744|OSI-774|R 1415|Tarceva®
OSI 744
OSI 774
OSI-774
R 1415
R-1415
RG-1415
RO-508231
Tarceva
|
|
19 |
|
Aflibercept |
Approved |
Phase 2 |
|
862111-32-8 |
124490314 |
Synonyms:
AFLIBERCEPT
AFLIBERCEPT (GENETICAL RECOMBINATION)
AVE0005
AVE-0005
BAY86-5321
BAY-865321
|
BAY-86-5321
EYLEA
VEGF TRAP
VEGF TRAP-EYE
ZALTRAP
ZIV-AFLIBERCEPT
|
|
20 |
|
Thalidomide |
Approved, Investigational, Withdrawn |
Phase 2 |
|
50-35-1 |
5426 |
Synonyms:
(+-)-N-(2,6-DIOXO-3-PIPERIDYL)PHTHALIMIDE
(+-)-THALIDOMIDE
(±)-N-(2,6-DIOXO-3-PIPERIDYL)PHTHALIMIDE
(±)-THALIDOMIDE
1,3-DIOXO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE
2,6-DIOXO-3-PHTHALIMIDOPIPERIDINE
3-PHTHALIMIDOGLUTARIMIDE
Algosediv
ALPHA-(N-PHTHALIMIDO)GLUTARIMIDE
ALPHA-N-PHTHALYLGLUTARAMIDE
alpha-Phthalimidoglutarimide
Asidon 3
Asmadion
Asmaval
Bonbrain
Bonbrrin
Calmore
Calmorex
Celgene brand OF thalidomide
Contergan
Corronarobetin
Distaval
Distaxal
Distoval
Ectiluran
Enterosediv
Gastrinide
Glupan
Glutanon
Grippex
Hippuzon
Imida-Lab
Imidan
Imidene
Isomin
K-17
Kedavon
Kevadon
Lulamin
N-(2,6-DIOXO-3-PIPERIDYL)PHTHALIMIDE
Neaufatin
Neo
Neosedyn
Neosydyn
Nerosedyn
Neufatin
Neurodyn
Neurosedin
Neurosedym
Neurosedyn
Nevrodyn
Nibrol
Noctosediv
Noxodyn
|
N-Phthalimidoglutamic acid imide
N-Phthaloylglutamimide
N-Phthalylglutamic acid imide
N-PHTHALYL-GLUTAMINSAEURE-IMID
NSC-527179
NSC-66847
Pangul
Pantosediv
Poly-Giron
Polygripan
Predni-Sediv
Pro-ban M
Profarmil
Psycholiquid
Psychotablets
Quetimid
Quietoplex
Sandormin
Sedalis
Sedalis sedi-lab
Sedimide
Sedin
Sedisperil
Sedoval
Shin-naito S
Shinnibrol
Sleepan
Slipro
Softenil
Softenon
Talargan
TALIDEX
TALIDOMIDA
Talimol
Talismol
Telagan
Telargan
Telargean
Tensival
Thaled
Thalidomide
THALIDOMIDUM
Thalidomine usp26
Thalin
Thalinette
Thalomid
Theophilcholine
Valgis
Valgraine
Yodomin
Α-(N-PHTHALIMIDO)GLUTARIMIDE
Α-N-PHTHALYLGLUTARAMIDE
Α-PHTHALIMIDOGLUTARIMIDE
|
|
21 |
|
Sorafenib |
Approved, Investigational |
Phase 2 |
|
284461-73-0 |
216239 |
Synonyms:
4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide
4-(4-(3-(4-Chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxylic acid methyamide-4-methylbenzenesulfonate
4-(4-(3-(4-Chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate
BAY 43-9006
BAY 43-9006|BAY-439006|Nexavar®
BAY-43-9006
N-(4-Chloro-3-(trifluoromethyl)phenyl)-n'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
|
Nexavar
SORAFENIB
Sorafénib
Sorafenib N oxide
Sorafenib N-oxide
Sorafenib tosylate
Sorafenibum
|
|
22 |
|
Coenzyme M |
Approved, Investigational |
Phase 2 |
|
3375-50-6 |
598 23662354 |
Synonyms:
1-THIOETHANEsulfonate
1-THIOETHANEsulfonIC ACID
1-THIOETHANEsulphonate
1-THIOETHANEsulphonic acid
2 Mercaptoethanesulfonate
2-Mercaptoethane
2-Mercaptoethanesulfonate
2-Mercaptoethanesulfonic acid
2-Mercaptoethanesulphonate
2-Mercaptoethanesulphonate, sodium
2-Mercaptoethanesulphonic acid
2-Mercaptoethylsulfonate
2-Mercaptoethylsulfonic acid
2-Mercaptoethylsulphonate
2-Mercaptoethylsulphonic acid
2-Sulfanylethylsulfonate
2-Sulfanylethylsulfonic acid
2-Sulphanylethylsulphonate
2-Sulphanylethylsulphonic acid
ASTA D 7093
ASTA medica brand OF mesna
ASTAD 7093
ASTA-D 7093
beta-Mercaptoethanesulfonate
beta-Mercaptoethanesulfonic acid
beta-Mercaptoethanesulphonate
beta-Mercaptoethanesulphonic acid
b-Mercaptoethanesulfonate
b-Mercaptoethanesulfonic acid
b-Mercaptoethanesulphonate
b-Mercaptoethanesulphonic acid
Bristol myers squibb brand OF mesna
|
Bristol-myers squibb brand OF mesna
Cell pharm brand OF mesna
Coenzima m
Coenzym m
Coenzyme m
CoM
D-7093
HS-CoM
Kendrick brand OF mesna
Mesna
MESNA cell
Mesna kendrick brand
Mesna sanfer brand
MESNA-cell
Mesnex
Mesnum
Mistabron
Mistabronco
Mitexan
Mucofluid
NSC-113891
Reduced coenzyme m
Reduced com
Sanfer brand OF mesna
Sodium 2-mercaptoethanesulphonate
UCB brand OF mesna
Uromitexan
Ziken
Β-mercaptoethanesulfonate
Β-mercaptoethanesulfonic acid
Β-mercaptoethanesulphonate
Β-mercaptoethanesulphonic acid
|
|
23 |
|
Docetaxel |
Approved, Investigational |
Phase 2 |
|
114977-28-5 |
148124 |
Synonyms:
CKD-810
Docecad®|docetaxel anhydrous|EmDOC|Taxotere®
DOCEFREZ
DOCETAXEL
Docetaxel anhydrous
Docetaxel hydrate
Docetaxel trihydrate
Docetaxel, trihydrate
Docetaxol
N Debenzoyl N tert butoxycarbonyl 10 deacetyltaxol
|
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-Debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol
NSC-628503
RP-56976
TAXCEUS
Taxoltere metro
Taxotere
TXL
XRP6976
|
|
24 |
|
Lenvatinib |
Approved, Investigational |
Phase 2 |
|
417716-92-8 |
9823820 |
Synonyms:
4-(3-chloro-4-((Cyclopropylaminocarbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide
4-(3-Chloro-4-(n'-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide
4-{3-CHLORO-4-[(CYCLOPROPYLCARBAMOYL)AMINO]PHENOXY}-7-METHOXYQUINOLINE-6-CARBOXAMIDE
e 7080
E 7080|ER-203492-00|Kisplyx®|Lenvima®
e7080
E-7080
|
ER-203492-00
KISPLYX
LENVATINIB
LENVATINIB MESYLATE
Lenvima
UNII-ee083865g2
|
|
25 |
|
Fulvestrant |
Approved, Investigational |
Phase 1, Phase 2 |
|
129453-61-8 |
17756771 104741 |
Synonyms:
(1S,9R,11S,14S,15S)-15-Methyl-9-[9-(4,4,5,5,5-pentafluoropentanesulphinyl)nonyl]tetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-2,4,6-triene-5,14-diol
(7α,17β)-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1(10),2,4-triene-3,17-diol
7-(9-(4,4,5,5,5-Pentafluoropentylsulfinyl)nonyl)estra-1,3,5(10)-triene-3,17-diol
Faslodex
Faslodex®|ICI 182,780|ICI 182780|ICI182780|ZD-9238
|
FULVESTRANT
ICI 182,780
ICI-182780
SID29215034
ZD-9238
|
|
26 |
|
Iodine |
Approved, Investigational |
Phase 2 |
|
7553-56-2 |
807 |
Synonyms:
Cadex
Diiodine
I2
Iode
Iodine
Iodine 127
Iodine-127
Iodine-molecule
|
Iodio
iodo
Iodum
Jod
Jood
Molecular iodine
NSC-42355
Tincture iodine
|
|
27 |
|
Durvalumab |
Approved, Investigational |
Phase 2 |
|
1428935-60-7 |
|
Synonyms:
|
28 |
|
Tremelimumab |
Approved, Investigational |
Phase 2 |
|
745013-59-6 |
|
Synonyms:
CP-675,206
CP-675|CP-675,206|CP-675206|ticilimumab
CP-675206
|
TICILIMUMAB
TREMELIMUMAB
TREMELIMUMAB (GENETICAL RECOMBINATION)
|
|
29 |
|
Atezolizumab |
Approved, Investigational |
Phase 2 |
|
1380723-44-3 |
|
Synonyms:
ANTI-PDL1
ANTI-PD-L1
ATEZOLIZUMAB
MPDL3280A
|
MPDL-3280A
RG-7446
TECENTRIQ
|
|
30 |
|
Rucaparib |
Approved, Investigational |
Phase 2 |
|
283173-50-2 |
9931954 |
Synonyms:
AG014699
AG-014699
AG-014699|AG014699|AG14447|PF-01367338|Rubraca®
AG14447
AG-14447
|
AG-14447ag-014699Rucaparib
PF-01367338
Rubraca
RUCAPARIB
Rucaparibum
|
|
31 |
|
Olaparib |
Approved |
Phase 2 |
|
763113-22-0 |
23725625 |
Synonyms:
1-(CYCLOPROPYLCARBONYL)-4-[5-[(3,4-DIHYDRO-4-OXO-1-PHTHALAZINYL)METHYL]-2-FLUOROBENZOYL]PIPERAZINE
4-(3-{[4-(CYCLOPROPYLCARBONYL)PIPERAZIN-1-YL]CARBONYL}-4-FLUOROBENZYL)PHTHALAZIN-1(2H)-ONE
AZ2281
AZ-2281
AZD2281
AZD-2281
AZD-2281|AZD2281|Lynparza®
|
KEYLYNK-010 COMPONENT OLAPARIB
KU-0059436
KU59436
KU-59436
Lynparza
OLAPARIB
OLAPARIB COMPONENT OF KEYLYNK-010
|
|
32 |
|
Metformin |
Approved |
Phase 2 |
|
1115-70-4, 657-24-9 |
4091 |
Synonyms:
[<sup>14</sup>C]-metformin
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
1-CARBAMIMIDAMIDO-N,N-DIMETHYLMETHANIMIDAMIDE
Apo-Metformin
BOLAMYN SR
Diabefagos
Diabex
Diaformin
DIAGEMET XL
Dianben
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
DMBG
Fortamet
Gen-Metformin
GLUCAMET 500
GLUCAMET 850
GLUCIENT SR
Glucophage
GLUCOPHAGE SR
GLUCOPHAGE XR
Glumetza
Glycon
GLYFORMIN
HCL, Metformin
Hydrochloride, metformin
JANUMET
LA 6023
LA-6023
|
LEDERMETIN
Meguan
METABET SR
Metformin
Metformin HCL
Metformin hydrochloride
Metformina
Metformine
Metforminum
Metiguanide
METSOL
MILFORM
Mylan-Metformin
N(1),N(1)-Dimethylbiguanide
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylguanylguanidine
N,N-Dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
Novo-Metformin
NSC-91485
Nu-Metformin
Obimet
ORABET
PMS-Metformin
Ran-Metformin
Ratio-Metformin
Riomet
Sandoz Metformin
SUKKARTO SR
Teva-Metformin
XLA399
|
|
33 |
|
Doxycycline |
Approved, Investigational, Vet_approved |
Phase 2 |
|
564-25-0 |
54671203 |
Synonyms:
(4S,4AR,5S,5ar,6R,12as)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
5-Hydroxy-a-6-deoxytetracycline
5-Hydroxy-alpha-6-deoxytetracycline
5-Hydroxy-α-6-deoxytetracycline
6a-Deoxy-5-oxytetracycline
6-alpha-deoxy-5-oxytetracycline
6alpha-Deoxy-5-oxytetracycline
6Α-deoxy-5-oxytetracycline
Anhydrous doxycycline
BMY-28689|Monodox®|Vibramycin®
Doxcycline anhydrous
Doxiciclina
DOXY
Doxychel
Doxycyclin
Doxycycline
|
Doxycycline (anhydrous)
DOXYCYCLINE ANHYDROUS
DOXYCYCLINE HCL
Doxycycline hyclate
Doxycycline hydrate
Doxycycline hydric acid
Doxycycline monohydrate
Doxycycline monohydric acid
Doxycyclinum
Doxytetracycline
GS-3065
Jenacyclin
Monodox
Oracea
Supracyclin
Vibramycin
|
|
34 |
|
Bevacizumab |
Approved, Investigational |
Phase 2 |
|
216974-75-3 |
135329020 |
Synonyms:
12-IGG1
ANTIVEGF
Anti-VEGF Humanized Monoclonal Antibody
Anti-VEGF monoclonal antibody
AVA-1
AVASTIN
Bevacizumab
BEVACIZUMAB BETA
bevacizumab-awwb
|
BI 695502
BS-503A
FKB-238
HLX04
HLX-04
R-435
RG-435
RHUMAB-
rhuMAb-VEGF
|
|
35 |
|
Pembrolizumab |
Approved |
Phase 2 |
|
1374853-91-4 |
254741536 |
Synonyms:
KEYLYNK-010 COMPONENT PEMBROLIZUMAB
KEYTRUDA
Keytruda®|lambrolizumab|MK-3475
LAMBROLIZUMAB
|
MK-3475
PEMBROLIZUMAB
PEMBROLIZUMAB COMPONENT OF KEYLYNK-010
SCH-900475
|
|
36 |
|
Cisplatin |
Approved |
Phase 2 |
|
15663-27-1 |
2767 5702198 441203 |
Synonyms:
Abiplatin
Biocisplatinum
Briplatin
CACP
Carboquone
CDDP
Cis Pt II
cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
CIS-DIAMMINEDICHLOROPLATINUM(II)
Cismaplat
CISPLATIN
Cisplatine
cisplatino
CISPLATINUM
CIS-PLATINUM II
Cisplatyl
Citoplationo
CPDC
CPDD
DDP
DDPT
|
Diamminedichloroplatinum
INT230-6 COMPONENT CISPLATIN
INT-230-6 COMPONENT CISPLATIN
Lederplatin
Neoplatin
NSC-119875
Plastin
Platamine
Platiblastin
Platidiam
Platinex
PLATINOL
PLATINOL-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
|
|
37 |
|
Sirolimus |
Approved, Investigational |
Phase 2 |
|
53123-88-9 |
5284616 6436030 |
Synonyms:
(-)-Rapamycin
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-{(2S)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl}-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0(4,9)]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
Antibiotic ay 22989
AY-22989
AY-22989|Fyarro® (sirolimus albumin-bound particles)|Rapamune®|rapamycin|WY-090217
L04AA10
NSC-226080
Perceiva
RAPA
Rapammune
|
Rapamune
Rapamycin
Rapamysin
RPM
Sirolimus
Sirolimús
Sirolimusum
SM-88 COMPONENT SIROLIMUS
WY-090217
|
|
38 |
|
Miconazole |
Approved, Investigational, Vet_approved |
Phase 2 |
|
22916-47-8 |
4189 |
Synonyms:
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
Brentan
CONOFITE
Dactarin
DERMAZOLE
DUMICOAT
Esteve brand OF miconazole
florid(nitrate)|Monistat®|R-14889
Janssen cilag brand OF miconazole
Janssen-cilag brand OF miconazole
Johnston and johnston brand OF miconazole nitrate
LORAMYC
MCZ
MICATIN
|
Miconasil nitrate
Miconazol
Miconazole
Miconazole esteve brand
Miconazole janssen-cilag brand
Miconazole nitrate
Miconazolum
Monistat
MONISTAT-3
MONISTAT-DERM
Nitrate, miconasil
Nitrate, miconazole
NSC-170986
Oravig
VUSION
|
|
39 |
|
Clotrimazole |
Approved, Vet_approved |
Phase 2 |
|
23593-75-1 |
2812 |
Synonyms:
(Chlorotrityl)imidazole
1-((2-Chlorophenyl)diphenylmethyl)-1H-imidazole
1-(a-(2-Chlorophenyl)benzhydryl)imidazole
1-(alpha-(2-Chlorophenyl)benzhydryl)imidazole
1-(O-Chloro-a,a-diphenylbenzyl)imidazole
1-(O-Chloro-alpha,alpha-diphenylbenzyl)imidazole
1-(O-Chlorotrityl)imidazole
1-(O-Chloro-α,α-diphenylbenzyl)imidazole
1-(Α-(2-chlorophenyl)benzhydryl)imidazole
ABTRIM
ACTAVALL
Bay b 5097
BAY-5097
Bayer brand 1 OF clotrimazole
Bayer brand 2 OF clotrimazole
CANDIDEN
Canesten
Canesten 1-day cream combi-pak
Canesten 1-day therapy
Canesten 3-day therapy
Canesten 6-day therapy
CANESTEN AF
Canesten combi-pak 1-day therapy
Canesten combi-pak 3-day therapy
Canesten cream
CANESTEN CRM COMBI
CANESTEN INTERNAL
Canesten solution
CANESTEN VC
Canesten®|Lotrimin®
Canestine
Chlotrimazole
Clotrimaderm
Clotrimaderm cream
Clotrimazol
CLOTRIMAZOLE
Clotrimazole schering brand
Clotrimazolum
Desamix F
Empecid
FB b 5097
Fem care
FemCare
FUNGEDERM
GNF-PF-3499
Gyne lotrimin
Gyne-lotrimin
Gyne-lotrimin 3
Gyne-lotrimin 3 combination pack
Gyne-lotrimin combination pack
Gyne-lotrimin3
Gyne-lotrimin3 combination pack
|
Gynix
Kanesten
Klotrimazole
Lopac-C-6019
Lotrimax
Lotrimin
LOTRIMIN (TN)
Lotrimin af
Lotrimin af cream
Lotrimin af jock-itch cream
Lotrimin af lotion
Lotrimin af solution
Lotrimin cream
Lotrimin lotion
Lotrimin solution
Lotrisone
MASNODERM
mono-Baycuten
Monobaycuten
Mycelax
Mycelex
MYCELEX (TN)
Mycelex 7
Mycelex cream
Mycelex g
Mycelex otc
Mycelex solution
Mycelex troches
Mycelex twin pack
Mycelex: mycosporinrimazole
Mycelex-7
Mycelex-7 combination pack
Mycelex-g
MYCIL GOLD
Myclo cream
Myclo solution
Myclo spray solution
Myclo-gyne
Mycosporin
Mykosporin
Neo-zol cream
NSC-257473
Otomax
Pedisafe
Prestwick_120
PRIVACOM
Rimazole
Schering brand OF clotrimazole
Tibatin
Trimysten
Trivagizole 3
Veltrim
|
|
40 |
|
Vorinostat |
Approved, Investigational |
Phase 2 |
|
149647-78-9 |
5311 |
Synonyms:
18F Suberoylanilide hydroxamic acid
18F-SAHA
18F-Suberoylanilide hydroxamic acid
Merck brand OF vorinostat
MK0683
MK-0683
MK-0683|MK0683|SAHA|suberoylanilide hydroxamic acid|Zolinza®
N Hydroxy n' phenyloctanediamide
N1 Hydroxy N8 phenyloctanediamide
N1-Hydroxy-N8-phenyloctanediamide
NHNPODA
N-Hydroxy-n'-phenyloctanediamide
N-Hyrdroxy-n'-phenyloctanediamide
|
Octanedioate hydroxyamide phenylamide
Octanedioic acid hydroxyamide phenylamide
SAHA
SHH
Suberanilohydroxamate
Suberanilohydroxamic acid
Suberoyl anilide hydroxamic acid
Suberoylanilide hydroxamate
Suberoylanilide hydroxamic acid
VORINOSTAT
Vorinostatum
Zolinza
|
|
41 |
|
Iniparib |
Investigational |
Phase 2 |
|
160003-66-7 |
9796068 |
Synonyms:
4-iodo-3-nitrobenzamide
4-Iodo-3-nitrobenzene-1-carboximidate
BSI 201
|
BSI-201
Iniparib
SAR240550
|
|
42 |
|
Rivoceranib |
Investigational |
Phase 2 |
|
811803-05-1 |
11315474 |
Synonyms:
APATINIB
apatinib (in China)|YN968D1
Apatinib mesylate
Rivoceranib
|
Rivoceranib mesylate
YN968D1
YN968D1 free base
|
|
43 |
|
MK-1775 |
Investigational |
Phase 2 |
|
955365-80-7 |
24856436 |
Synonyms:
2-Allyl-1-(6-(2-hydroxy-2-propanyl)-2-pyridinyl)-6-((4-(4-methyl-1-piperazinyl)phenyl)amino)-1,2-dihydro-3H-pyrazolo(3,4-D)pyrimidin-3-one
ADAVOSERTIB
AZD 1775
AZD 1775|AZD-1775|AZD1775|MK-1775|MK1775
|
|
|
44 |
|
Linrodostat |
Investigational |
Phase 2 |
|
1923833-60-6 |
121328278 |
Synonyms:
BMS-986205
BMS-986205|BMS986205|Compound 2 [PMID: 29531094]|Example 19 [US20160137652A1]
|
|
|
45 |
|
Cediranib |
Investigational |
Phase 2 |
|
288383-20-0 |
9933475 |
Synonyms:
4-((4-Fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline
4-(4-FLUORO-2-METHYLINDOL-5-YLOXY)-6-METHOXY-7-[3-(PYRROLIDIN-1-YL)PROPOXY]QUINAZOLINE
AZD 2171
AZD 2171|AZD2171|ZD 2171
AZD-2171
|
CEDIRANIB
RECENTIN
ZD 2171
ZD-2171
|
|
46 |
|
Liver Extracts |
|
Phase 2 |
|
|
|
47 |
|
Imatinib Mesylate |
|
Phase 2 |
|
220127-57-1 |
|
Synonyms:
GLEEVEC
GLIVEC
IMATINIB MESILATE
IMATINIB MESYLATE
|
IMATINIB METHANESULFONATE
STI571
STI-571
|
|
48 |
|
Epothilones |
|
Phase 2 |
|
|
|
49 |
|
Epothilone B |
|
Phase 2 |
|
|
4456137 |
50 |
|
Antiviral Agents |
|
Phase 2 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 69)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
A Multicentric Randomized Phase II/III Evaluating TSR-042 (Anti-PD-1 mAb) in Combination With Niraparib (Parpi) Versus Niraparib Alone Compared to Chemotherapy in the Treatment of Metastatic or Recurrent Endometrial or Ovarian Carcinosarcoma After at Least One Line of Chemotherapy |
Recruiting |
NCT03651206 |
Phase 2, Phase 3 |
Niraparib;Chemotherapy Drugs |
2 |
A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-Oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma |
Recruiting |
NCT05256225 |
Phase 2, Phase 3 |
Carboplatin;Hyaluronidase-zzxf/Pertuzumab/Trastuzumab;Paclitaxel;Trastuzumab/Hyaluronidase-oysk |
3 |
A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary |
Active, not recruiting |
NCT00954174 |
Phase 3 |
Carboplatin;Ifosfamide;Paclitaxel |
4 |
A Phase II Multicenter Trial of Paclitaxel and Carboplatin in Women With Advanced (IIIb, IIIc, IVa and IVb) or Recurrent (All Stages) Malignant Mixed Mullerian Tumors (MMMT) of the Uterus |
Completed |
NCT00502203 |
Phase 2 |
Carboplatin;Paclitaxel |
5 |
Phase II Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS) |
Completed |
NCT02993705 |
Phase 2 |
Trabectedin |
6 |
A Phase 2 Study of Sunitinib Malate in Recurrent or Metastatic Endometrial Carcinoma |
Completed |
NCT00478426 |
Phase 2 |
Sunitinib Malate |
7 |
A Phase II Study of Oxaliplatin and Gemcitabine Followed by Radiation Therapy in the Management of Mixed Mullerian Tumors of the Uterus |
Completed |
NCT00476086 |
Phase 2 |
Gemcitabine;Oxaliplatin |
8 |
Phase II Study Evaluating PegLiposomal Doxorubicin (PLD) and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors |
Completed |
NCT00815945 |
Phase 2 |
PegLiposomal Doxorubicin;Carboplatin |
9 |
A Randomized Phase II Trial of Avastin (A) or Avastin and Erlotinib (AE) as First Line Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Newly Diagnosed Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors |
Completed |
NCT00520013 |
Phase 2 |
bevacizumab;erlotinib;paclitaxel;carboplatin |
10 |
Phase II Study of Paclitaxel (TAXOL), Intraperitoneal Cisplatin and IV Avastin Followed by Avastin Consolidation for Advanced Ovarian and Peritoneal Carcinoma or Fallopian Tube Cancer |
Completed |
NCT00511992 |
Phase 2 |
Avastin;Paclitaxel;Cisplatin |
11 |
A Phase II Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma |
Completed |
NCT00687687 |
Phase 2 |
paclitaxel;carboplatin;BSI-201 (Iniparib) |
12 |
A Phase II Study of VEGF-Trap in Recurrent or Metastatic Gynecologic Soft-Tissue Sarcomas |
Completed |
NCT00390234 |
Phase 2 |
ziv-aflibercept |
13 |
A Phase II Evaluation of Thalidomide (NSC #66847) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus |
Completed |
NCT00025506 |
Phase 2 |
Thalidomide |
14 |
A Phase II Study of BAY 43-9006 in Advanced/Recurrent Uterine Carcinoma/Carcinosarcoma |
Completed |
NCT00238121 |
Phase 2 |
sorafenib tosylate |
15 |
A Pilot Phase II Trial of Adjuvant Radiation Therapy "Sandwiched" Between Ifosfamide in Patients With Mixed Mesodermal Tumors |
Completed |
NCT00231842 |
Phase 2 |
Ifosfamide;Cisplatin |
16 |
A Phase 2 Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer |
Completed |
NCT01010126 |
Phase 2 |
Temsirolimus |
17 |
A Phase II Evaluation of Gemcitabine (NSC #613327) and Docetaxel (NSC # 628503) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus |
Completed |
NCT00114218 |
Phase 2 |
Gemcitabine Hydrochloride;Docetaxel |
18 |
A Phase II Evaluation of Gleevec(TM) (NCI-Supplied Agent: STI571 [Imatinib Mesylate], NSC# 716051) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus |
Completed |
NCT00075400 |
Phase 2 |
imatinib mesylate |
19 |
A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial, Epithelial Ovarian Cancer, or Carcinosarcoma |
Completed |
NCT03395080 |
Phase 2 |
Paclitaxel;300mg DKN-01;600mg DKN-01 |
20 |
A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus |
Completed |
NCT01247571 |
Phase 2 |
Pazopanib Hydrochloride |
21 |
A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus |
Completed |
NCT01168232 |
Phase 2 |
Ixabepilone |
22 |
A Non-randomized, Open-label, Multi-center, Phase I/II Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Copanlisib in Pediatric Patients With Relapsed/Refractory Solid Tumors or Lymphoma |
Recruiting |
NCT03458728 |
Phase 1, Phase 2 |
BAY806946 |
23 |
A Phase II Trial of Pembrolizumab Plus Olaparib for the Treatment of Patients With Persistent/Recurrent Endometrial Cancers |
Recruiting |
NCT05156268 |
Phase 2 |
Pembrolizumab;Olaparib |
24 |
A Phase II Trial of Pembrolizumab Plus Lenvatinib for the Treatment of Patients With Advanced Uterine and Ovarian Carcinosarcomas |
Recruiting |
NCT05147558 |
Phase 2 |
Pembrolizumab;Lenvatinib |
25 |
A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients With Advanced Solid Tumors |
Recruiting |
NCT05252416 |
Phase 1, Phase 2 |
BLU-222;Carboplatin;Ribociclib;Fulvestrant |
26 |
A Multicenter, Open, Single Arm, Phase II Clinical Study of Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma |
Recruiting |
NCT05265793 |
Phase 2 |
Camrelizumab Combined With Apatinib |
27 |
A Phase II Trial of Nivolumab for Recurrent/Metastatic Carcinosarcoma |
Recruiting |
NCT05224999 |
Phase 2 |
nivolumab |
28 |
MC1365, A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer |
Recruiting |
NCT02364713 |
Phase 2 |
Gemcitabine Hydrochloride;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride |
29 |
A Phase 2 Study of the Wee1 Inhibitor AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma |
Recruiting |
NCT03668340 |
Phase 2 |
AZD1775 |
30 |
Pazopanib vs. Pazopanib Plus Gemcitabine in Patients With Relapsed or Metastatic Uterine Leiomyosarcomas or Uterine Carcinosarcomas: a Multi-center, Randomized Phase-II Clinical Trial of the NOGGO and AGO - PazoDoble - |
Recruiting |
NCT02203760 |
Phase 2 |
Pazopanib plus Gemcitabine;Pazopanib |
31 |
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors |
Recruiting |
NCT02834013 |
Phase 2 |
|
32 |
A Phase 2 Trial of ZW25 in HER2 Overexpressed Advanced Endometrial Cancers and Carcinosarcomas (ZW25-IST-2) |
Recruiting |
NCT04513665 |
Phase 2 |
ZW25 |
33 |
A Phase 2 Trial of Durvalumab [MEDI4736](Anti-PD-L1 Antibody) With or Without Tremelimumab (Anti-CTLA-4 Antibody) in Patients With Persistent or Recurrent Endometrial Carcinoma and Endometrial Carcinosarcoma |
Active, not recruiting |
NCT03015129 |
Phase 2 |
Durvalumab;Tremelimumab |
34 |
An Open Label, Non-Randomized Multisite Phase II Trial Combining Bevacizumab, Atezolizumab and Rucaparib for the Treatment of Previously Treated Recurrent and Progressive Endometrial Carcinoma |
Active, not recruiting |
NCT03694262 |
Phase 2 |
Rucaparib;Bevacizumab;Atezolizumab |
35 |
A Phase II Trial of IDO-Inhibitor, BMS-986205, and PD-1 Inhibitor, Nivolumab, in Patients With Recurrent or Persistent Endometrial Cancer or Endometrial Carcinosarcomas (CA017-056) |
Active, not recruiting |
NCT04106414 |
Phase 2 |
Nivolumab;BMS- 986205 |
36 |
A 3-Arm Randomised Phase II Evaluation of Cediranib in Combination With Weekly Paclitaxel or Olaparib Versus Weekly Paclitaxel Chemotherapy for Advanced Endometrial Carcinoma or for Disease Relapse Within 18 Months of Adjuvant Carboplatin-paclitaxel Chemotherapy. |
Active, not recruiting |
NCT03570437 |
Phase 2 |
Paclitaxel;Cediranib;Olaparib |
37 |
An International Multi-centre Randomised Phase II Study to Assess the Efficacy of TAK228 in Combination With Intravenous Weekly Paclitaxel Compared With Weekly Paclitaxel Alone in Women With Advanced/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) |
Active, not recruiting |
NCT03648489 |
Phase 2 |
Paclitaxel;TAK228 |
38 |
A Phase II Study of Metformin in Combination With Doxycycline in Patients With Localized Breast, and Uterine, and Cervical Cancer |
Active, not recruiting |
NCT02874430 |
Phase 2 |
Metformin Hydrochloride;Doxycycline |
39 |
A Phase Ib/II Single Arm Study of Cabozantinib Plus Dostarlimab in Women With Recurrent Gynecologic Carcinosarcoma |
Not yet recruiting |
NCT05559879 |
Phase 1, Phase 2 |
Cabo + Dostarlimab |
40 |
The EPOCH Study: Phase II Open Labelled Study Investigating the Use of Single Agent Eribulin and Eribulin in Combination With Pembrolizumab in Relapsed Tubo-ovarian or Uterine Carcinosarcoma |
Not yet recruiting |
NCT05619913 |
Phase 2 |
Eribulin Mesylate;Pembrolizumab |
41 |
Randomized Phase 2 Trial of APL-2 With Pembrolizumab vs. APL-2 With Pembrolizumab and Bevacizumab vs. Bevacizumab Alone in Patients With Recurrent Ovarian Cancer and Persistent Malignant Effusion |
Not yet recruiting |
NCT04919629 |
Phase 2 |
|
42 |
Pamiparib in Combination With Surufatinib in Patients With Platinum-resistant Ovarian Cancer Who Received Prior Poly (ADP-ribose) Polymerase (PARP) Inhibitors: a Multicenter, Single-arm, Phase Ib/II Trial |
Not yet recruiting |
NCT05494580 |
Phase 1, Phase 2 |
Pamiparib;Surufatinib |
43 |
A Phase II Study of Adjuvant Postoperative Radiation With Cisplatin Followed by Carboplatin/Paclitaxel Chemotherapy Following Total Abdominal Hysterectomy/Bilateral Salpino-Oophorectomy (TAH/BSO) for Patients With Stage I, II and IIIa Malignant Mixed Mesodermal Tumor (MMMT) of the Uterus. |
Terminated |
NCT00505492 |
Phase 2 |
Carboplatin;Cisplatin;Paclitaxel |
44 |
A Phase II Study of Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer |
Terminated |
NCT00322881 |
Phase 2 |
Paclitaxel;Carboplatin |
45 |
Pilot Phase II Study of Temsirolimus in Patients With Recurrent Mixed Mesodermal and Mullerian Tumors (Carcinosarcoma) of the Uterus |
Terminated |
NCT01061606 |
Phase 2 |
temsirolimus |
46 |
A Pilot Study of Peroral Vorinostat (SAHA) in Patients With Refractory Histone Deacetylase-positive Uterine Sarcoma |
Terminated |
NCT03509207 |
Phase 2 |
Vorinostat Oral Capsule |
47 |
Phase II Trial of Postoperative Radiotherapy and Panitumumab in High-risk Salivary Gland Malignancies |
Withdrawn |
NCT00984217 |
Phase 2 |
Panitumumab |
48 |
A Phase II Single Arm Study of Cabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic Carcinosarcoma |
Withdrawn |
NCT04149275 |
Phase 2 |
Cabozantinib;Ipilimumab;Nivolumab |
49 |
A Phase II, Signal-Seeking Trial of the Clinical Benefit Rate Associated With Pamiparib in Subjects With Germline or Somatic BRCA1/2 High Grade Serous Ovarian Cancer or Carcinosarcoma Who Have Progressed on P-gp Substrate Chemotherapy or PARPi With the Presence of an ABCB1 Fusion and the Absence of a BRCA1/2 Reversion |
Withdrawn |
NCT03933761 |
Phase 2 |
Pamiparib |
50 |
A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma |
Unknown status |
NCT01454479 |
Phase 1 |
Lapatinib and ixempra |
|